Khloris Biosciences, Inc. products

iPSC vaccination presents a differentiated approach to cancer treatment, targeting a panoply of antigens, leveraging the patient`s immune system for optimized antigen presentation, and engaging both cellular and humoral responses

Khloris` iPSCs are optimized to generate high-functioning cardiomyocytes, enabling development of an allogeneic source of donor cells for patients with damaged heart tissue

By developing cardiomyocytes directly from patient-derived iPSCs, we create a non-invasive, personalized platform to directly observe the effects of drug therapies on heart tissue